41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
October 2025 in “Dermatology and Therapy”
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
4 citations
,
September 2018 in “The Journal of Dermatology” A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
16 citations
,
December 2012 in “Bioinformation” Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
15 citations
,
January 2014 in “Medicinal chemistry” Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
23 citations
,
November 2015 in “Phytotherapy Research” Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.